Login Register Cart 0
Generic placeholder image

Current Drug Targets

Editor-in-Chief

ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Xerostomia: Advances and Challenges in Drug Development

Author(s): Yoon-Jung Kim*

Volume 25, Issue 5, 2024

Published on: 28 February, 2024

Page: [301 - 305] Pages: 5

DOI: 10.2174/0113894501293941240228050343

Next »
[1]
Ito K, Izumi N, Funayama S, et al. Characteristics of medication-induced xerostomia and effect of treatment. PLoS One 2023; 18(1): e0280224.
[http://dx.doi.org/10.1371/journal.pone.0280224] [PMID: 36634078]
[2]
Tanasiewicz M, Hildebrandt T, Obersztyn I. Xerostomia of various etiologies: A review of the literature. Adv Clin Exp Med 2016; 25(1): 199-206.
[http://dx.doi.org/10.17219/acem/29375] [PMID: 26935515]
[3]
Cho MA, Ko JY, Kim YK, Kho HS. Salivary flow rate and clinical characteristics of patients with xerostomia according to its aetiology. J Oral Rehabil 2010; 37(3): 185-93.
[http://dx.doi.org/10.1111/j.1365-2842.2009.02037.x] [PMID: 20002531]
[4]
Iwasaki M, Yoshihara A, Ito K, et al. Hyposalivation and dietary nutrient intake among community-based older J apanese. Geriatr Gerontol Int 2016; 16(4): 500-7.
[http://dx.doi.org/10.1111/ggi.12500] [PMID: 25952943]
[5]
Turner MD. Hyposalivation and xerostomia. Dent Clin North Am 2016; 60(2): 435-43.
[http://dx.doi.org/10.1016/j.cden.2015.11.003] [PMID: 27040294]
[6]
Sreebny LM. Salivary flow in health and disease. Compend Suppl 1989; (13): S461-9.
[PMID: 2691080]
[7]
Thomson WM, Smith MB, Ferguson CA, Moses G. The challenge of medication-induced dry mouth in residential aged care. Pharmacy 2021; 9(4): 162.
[http://dx.doi.org/10.3390/pharmacy9040162] [PMID: 34698291]
[8]
Ambudkar IS. Ca2+ signaling and regulation of fluid secretion in salivary gland acinar cells. Cell Calcium 2014; 55(6): 297-305.
[http://dx.doi.org/10.1016/j.ceca.2014.02.009] [PMID: 24646566]
[9]
Ambudkar IS. Calcium signalling in salivary gland physiology and dysfunction. J Physiol 2016; 594(11): 2813-24.
[http://dx.doi.org/10.1113/JP271143] [PMID: 26592972]
[10]
Nakamura T, Matsui M, Uchida K, et al. M 3 muscarinic acetylcholine receptor plays a critical role in parasympathetic control of salivation in mice. J Physiol 2004; 558(2): 561-75.
[http://dx.doi.org/10.1113/jphysiol.2004.064626] [PMID: 15146045]
[11]
Ma T, Song Y, Gillespie A, Carlson EJ, Epstein CJ, Verkman AS. Defective secretion of saliva in transgenic mice lacking aquaporin-5 water channels. J Biol Chem 1999; 274(29): 20071-4.
[http://dx.doi.org/10.1074/jbc.274.29.20071] [PMID: 10400615]
[12]
Krane CM, Melvin JE, Nguyen HV, et al. Salivary acinar cells from aquaporin 5-deficient mice have decreased membrane water permeability and altered cell volume regulation. J Biol Chem 2001; 276(26): 23413-20.
[http://dx.doi.org/10.1074/jbc.M008760200] [PMID: 11290736]
[13]
Tada J, Sawa T, Yamanaka N, et al. Involvement of vesicle-cytoskeleton interaction in AQP5 trafficking in AQP5-gene-transfected HSG cells. Biochem Biophys Res Commun 1999; 266(2): 443-7.
[http://dx.doi.org/10.1006/bbrc.1999.1828] [PMID: 10600522]
[14]
Ishikawa Y, Eguchi T, Skowronski MT, Ishida H. Acetylcholine acts on M3 muscarinic receptors and induces the translocation of aquaporin5 water channel via cytosolic Ca2+ elevation in rat parotid glands. Biochem Biophys Res Commun 1998; 245(3): 835-40.
[http://dx.doi.org/10.1006/bbrc.1998.8395] [PMID: 9588201]
[15]
Ambudkar IS. Polarization of calcium signaling and fluid secretion in salivary gland cells. Curr Med Chem 2012; 19(34): 5774-81.
[http://dx.doi.org/10.2174/092986712804143321] [PMID: 23061636]
[16]
Mikoshiba K, Hisatsune C, Futatsugi A, Mizutani A, Nakamura T, Miyachi K. The role of Ca2+ signaling in cell function with special reference to exocrine secretion. Cornea 2008; 27(S1): S3-8.
[http://dx.doi.org/10.1097/ICO.0b013e31817f246e] [PMID: 18813072]
[17]
Melvin JE, Yule D, Shuttleworth T, Begenisich T. Regulation of fluid and electrolyte secretion in salivary gland acinar cells. Annu Rev Physiol 2005; 67(1): 445-69.
[http://dx.doi.org/10.1146/annurev.physiol.67.041703.084745] [PMID: 15709965]
[18]
Kim YJ. Xerostomia and its cellular targets. Int J Mol Sci 2023; 24(6): 5358.
[http://dx.doi.org/10.3390/ijms24065358] [PMID: 36982432]
[19]
Noaiseh G, Baker JF, Vivino FB. Comparison of the discontinuation rates and side-effect profiles of pilocarpine and cevimeline for xerostomia in primary Sjögren’s syndrome. Clin Exp Rheumatol 2014; 32(4): 575-7.
[PMID: 25065774]
[20]
Łysik D , Laskowska NK , Bucki R , Tokajuk G , Mystkowska J . Artificial saliva: Challenges and future perspectives for the treatment of xerostomia. Int J Mol Sci 2019; 20(13): 3199.
[http://dx.doi.org/10.3390/ijms20133199] [PMID: 31261876]
[21]
Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000; 18(19): 3339-45.
[http://dx.doi.org/10.1200/JCO.2000.18.19.3339] [PMID: 11013273]
[22]
Felice FDE, Pranno N, Papi P, Brugnoletti O, Tombolini V, Polimeni A. Xerostomia and clinical outcomes in definitive intensity modulated radiotherapy (IMRT) versus three-dimensional conformal radiotherapy (3D-CRT) for head and neck squamous cell carcinoma: A meta-analysis. In Vivo 2020; 34(2): 623-9.
[http://dx.doi.org/10.21873/invivo.11816] [PMID: 32111762]
[23]
Alevizos I, Zheng C, Cotrim AP, et al. Late responses to adenoviral-mediated transfer of the aquaporin-1 gene for radiation-induced salivary hypofunction. Gene Ther 2017; 24(3): 176-86.
[http://dx.doi.org/10.1038/gt.2016.87] [PMID: 27996967]
[24]
Baum BJ, Alevizos I, Zheng C, et al. Early responses to adenoviral-mediated transfer of the aquaporin-1 cDNA for radiation-induced salivary hypofunction. Proc Natl Acad Sci 2012; 109(47): 19403-7.
[http://dx.doi.org/10.1073/pnas.1210662109] [PMID: 23129637]
[25]
Baum BJ, Tran SD. Synergy between genetic and tissue engineering: Creating an artificial salivary gland. Periodontol 2000 2006; 41(1): 218-23.
[http://dx.doi.org/10.1111/j.1600-0757.2006.00160.x] [PMID: 16686936]
[26]
Baum BJ, Zheng C, Alevizos I, et al. Development of a gene transfer-based treatment for radiation-induced salivary hypofunction. Oral Oncol 2010; 46(1): 4-8.
[http://dx.doi.org/10.1016/j.oraloncology.2009.09.004] [PMID: 19892587]
[27]
Alajbeg I, Falcão DP, Tran SD, et al. Intraoral electrostimulator for xerostomia relief: A long-term, multicenter, open-label, uncontrolled, clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 113(6): 773-81.
[http://dx.doi.org/10.1016/j.oooo.2012.01.012] [PMID: 22668705]
[28]
Abughanam G, Elkashty OA, Liu Y, Bakkar MO, Tran SD. Mesenchymal stem cells extract (MSCsE)-Based therapy alleviates xerostomia and keratoconjunctivitis sicca in sjogren’s syndrome-like disease. Int J Mol Sci 2019; 20(19): 4750.
[http://dx.doi.org/10.3390/ijms20194750] [PMID: 31557796]
[29]
Takashi I, Kanai R, Hasegawa K, Ogaeri T, Tran SD, Sumita Y. Recent progress in regenerative therapy for damaged salivary glands: From bench to bedside. Oral Dis 2023; 30(1): 38-49.
[30]
Kapourani A, Kontogiannopoulos KN, Barmpalexis P. A review on the role of pilocarpine on the management of xerostomia and the importance of the topical administration systems development. Pharmaceuticals 2022; 15(6): 762.
[http://dx.doi.org/10.3390/ph15060762] [PMID: 35745681]
[31]
Hamlar DD, Schuller DE, Gahbauer RA, et al. Determination of the efficacy of topical oral pilocarpine for postirradiation xerostomia in patients with head and neck carcinoma. Laryngoscope 1996; 106(8): 972-6.
[http://dx.doi.org/10.1097/00005537-199608000-00011] [PMID: 8699911]
[32]
Gibson J, Halliday JA, Ewert K, Robertson S. A controlled release pilocarpine buccal insert in the treatment of Sjögren’s syndrome. Br Dent J 2007; 202(7): E17-7.
[http://dx.doi.org/10.1038/bdj.2007.80] [PMID: 17273177]
[33]
Taweechaisupapong S, Pesee M, Aromdee C, Laopaiboon M, Khunkitti W. Efficacy of pilocarpine lozenge for post-radiation xerostomia in patients with head and neck cancer. Aust Dent J 2006; 51(4): 333-7.
[http://dx.doi.org/10.1111/j.1834-7819.2006.tb00453.x] [PMID: 17256309]
[34]
Gusmão GMAS, Borba PM, Galindo MA. Evaluation of a mucoadhesive pilocarpine tablet for the treatment of xerostomia: A randomized, double-blind, crossover clinical trial. Gen Dent 2021; 69(4): 19-26.
[35]
Sarideechaigul W, Priprem A, Limsitthichaikoon S, et al. Efficacy and safety of two artificial saliva-based polymers containing 0.1% pilocarpine for treatment of xerostomia: A randomized clinical pilot trial. J Clin Exp Dent 2021; 13(10): e994-e1000.
[http://dx.doi.org/10.4317/jced.58415] [PMID: 34667494]
[36]
Pereira RMS, Bastos MDR, Ferreira MP, et al. Topical pilocarpine for xerostomia in patients with head and neck cancer treated with radiotherapy. Oral Dis 2020; 26(6): 1209-18.
[http://dx.doi.org/10.1111/odi.13343] [PMID: 32248594]
[37]
Santos Polvora TL, De Sousa Pereira RM, Macedo AP, et al. Pilocarpine spray for the treatment of xerostomia: A randomized, double-blind, placebo-controlled trial. Oral Surg Oral Med Oral Pathol Oral Radiol 2018; 126(3): e47.
[http://dx.doi.org/10.1016/j.oooo.2018.02.057]
[38]
Beatris MV. The effects of pilocarpine mouthwash on vocal quality. IOSR J Pharm Biol Sci 2018; 13: 30-5.
[39]
Song JI, Park J-E, Kim H-K, Kim M-E, Kim K-S. Dose-and time-related effects of pilocarpine mouthwash on salivation. J Oral Med Pain 2017; 42(3): 72-80.
[http://dx.doi.org/10.14476/jomp.2017.42.3.72]
[40]
Park JE, Song C-W, Kim K-S, Kim M-E. Comparison of the effects of pilocarpine solution and tablet on salivary flow rate. J Oral Med Pain 2015; 40(1): 10-6.
[http://dx.doi.org/10.14476/jomp.2015.40.1.10]
[41]
Tanigawa T, Yamashita J, Sato T, et al. Efficacy and safety of pilocarpine mouthwash in elderly patients with xerostomia. Spec Care Dentist 2015; 35(4): 164-9.
[http://dx.doi.org/10.1111/scd.12105] [PMID: 25639487]
[42]
Kim JH, Ahn HJ, Choi JH, Jung DW, Kwon JS. Effect of 0.1% pilocarpine mouthwash on xerostomia: Double-blind, randomised controlled trial. J Oral Rehabil 2014; 41(3): 226-35.
[http://dx.doi.org/10.1111/joor.12127] [PMID: 24527846]
[43]
Tanaka A, Nakano H, Yoneto K, et al. Topical xerostomia treatment with hyaluronate sheets containing pilocarpine. Biol Pharm Bull 2022; 45(4): 403-8.
[http://dx.doi.org/10.1248/bpb.b21-00763] [PMID: 35370264]
[44]
Kim YJ, Jo Y, Lee YH, Park K, Park HK, Choi SY. Zn2+ stimulates salivary secretions via metabotropic zinc receptor ZnR/GPR39 in human salivary gland cells. Sci Rep 2019; 9(1): 17648.
[http://dx.doi.org/10.1038/s41598-019-54173-3] [PMID: 31776425]
[45]
Saitou M, Gaylord EA, Xu E, et al. Functional specialization of human salivary glands and origins of proteins intrinsic to human saliva. Cell Rep 2020; 33(7): 108402.
[http://dx.doi.org/10.1016/j.celrep.2020.108402] [PMID: 33207190]

Rights & Permissions Print Cite
Article Metrics
10
2
© 2024 Bentham Science Publishers | Privacy Policy